Amorphous Solid Dispersion for Pyrazole-Amide Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The compound of the formula [I] has poor oral absorbability due to its low solubility, which is influenced by meals and can lead to reduced exposure when administered under fasting conditions.
Innovation Solution
An amorphous solid dispersion of the compound of the formula [I] is created using a specific pharmaceutically acceptable polymer, such as HPMCAS, methylcellulose, or polyvinyl alcohol, to enhance its solubility and maintain it in an amorphous state.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the compound of the formula [I] is administered in crystal form, then the formulation is stable, but the oral absorbability is poor due to low solubility
Solution Approach 1:
The patent changes the physical state parameter of the compound from crystalline to amorphous form. This parameter change increases solubility and oral absorbability while the polymer matrix provides stability to prevent re-crystallization, thus resolving the contradiction between formulation stability and oral absorbability.
Solution Approach 2:
The patent creates a composite material system consisting of the compound of the formula [I] dispersed in a polymer matrix. This composite structure allows the compound to maintain amorphous state (improving solubility) while the polymer provides structural stability, resolving the contradiction between formulation stability and oral absorbability.
2Adaptability or versatility
If the compound is administered under fasting conditions, then the administration timing is flexible, but the exposure is reduced due to low solubility
Solution Approach 1:
The patent changes the physical state from crystalline to amorphous, which fundamentally alters the dissolution behavior. The amorphous form maintains high solubility regardless of fasting or fed conditions, enabling flexible administration timing without sacrificing oral exposure.
3Ease of operation
If the compound is converted to amorphous form to improve solubility, then the oral absorbability increases, but the compound may precipitate in acidic solution
Solution Approach 1:
The patent introduces a polymer as an intermediary substance that stabilizes the amorphous form. The polymer acts as a matrix that prevents molecular reorganization into crystalline structures, thereby preventing precipitation in acidic solutions while maintaining high solubility.
Solution Approach 2:
The patent uses the polymer matrix to provide beforehand protection against precipitation. The polymer creates a protective environment that prevents the amorphous compound from transitioning to crystalline form during storage and administration, cushioning against the harmful effect of precipitation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous solid dispersion exhibits improved solubility and oral absorbability, regardless of the presence or absence of bile acids, and maintains high bioavailability even when administered under fasting conditions.
Implementation Method 1
a solid dispersion capable of stably maintaining a compound of the formula (I) or a pharmaceutically acceptable salt thereof, or a hydrate thereof in an amorphous state is provided
Implementation Method 2
an amorphous form of a compound of the formula (I) or a pharmaceutically acceptable salt thereof, or a hydrate thereof with improved solubility as compared with crystals thereof can be provided
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention aims to provide a preparation containing a compound of the formula [I] or a pharmaceutically acceptable salt thereof or a hydrate thereof having improved pharmacokinetics, and a manufacturing method thereof. The present invention relates to a solid dispersion containing (1) an amorphous compound represented by the following formula [I]: or a pharmaceutically acceptable salt thereof or a hydrate thereof, and (2) one to four kinds of pharmaceutically acceptable polymers selected from the group consisting of hydroxypropylmethylcellulose acetate succinate, methylcellulose, hypromellose and polyvinyl alcohol, and a manufacturing method thereof.